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Abstract
Background: Transarterial chemoembolization is one of the most widely accepted interventional treatment options for
treatment of hepatocellular carcinoma. Still there is a lack of a standard protocol regarding the injected
chemotherapeutics. Survivin is an inhibitor of Apoptosis protein that functions to inhibit apoptosis, promote proliferation,
and enhance invasion. Survivin is selectively up-regulated in many human tumors. Small interfering RNA (siRNA) can
trigger an RNA interference response in mammalian cells and induce strong inhibition of specific gene expression
including Survivin. The aim of the study is to assess the effectiveness of the additional injection of Survivin siRNA to the
routine protocol of Transarterial Chemoembolization (TACE) for the treatment of hepatocellular carcinoma in a rat model.
Methods: The study was performed on 20 male ACI rats. On day 0 a solid Morris Hepatoma 3924A was subcapsullary
implanted in the liver. On day 12 MRI measurement of the initial tumor volume (V1) was performed. TACE was performed
on day 13. The rats were divided into 2 groups; Group (A, n = 10) in which 0.1 mg mitomycin, 0.1 ml lipiodol and 5.0 mg
degradable starch microspheres were injected in addition 2.5 nmol survivin siRNA were injected. The same agents were
injected in Group (B,=10) without Survivin siRNA. MRI was repeated on day 25 to assess the tumor volume (V2). The
tumor growth ratio (V2/V1) was calculated. Western blot and immunohistochemical analysis were performed.
Results: For group A the mean tumor growth ratio (V2/V1) was 1.1313 +/− 0.1381, and was 3.1911 +/− 0.1393 in group
B. A statistically significant difference between both groups was observed regarding the inhibition of tumor growth (P < 0.
0001) where Group A showed more inhibition compared to Group B. Similarly immunohistochemical analysis showed
significantly lower (p < 0.002) VEGF staining in group A compared to group B. Western Blot analysis showed a similar
difference in VEGF expression (P < 0.0001).
Conclusion: The additional injection of Survivin siRNA to the routine TACE protocol increased the inhibition of the
hepatocellular carcinoma growth in a rat animal model compared to regular TACE protocol.
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Background
Being one of the most common malignancies in the
world Hepatocellular carcinoma (HCC) is estimated to
be responsible for about one million deaths per year.
Owing to its rapid infiltrating growth and complicating
liver cirrhosis HCC usually have a poor prognosis [1].
Transarterial chemoembolization (TACE) is a widely ac-
cepted therapeutic option for HCC [2]. Survivin is an in-
hibitor of Apoptosis protein that functions to inhibit
apoptosis, promote proliferation, and enhance invasion
[3]. Under normal conditions Survivin is expressed in
embryonic and fetal tissues and is barely detectable in
most differentiated normal adult tissues [4]. In addition,
it has been shown that Survivin expression is present in
some normal adult tissue cells like T-Lymphocytes,
polymorphonuclear-neutrophils, primitive hematopoietic
cells and vascular endothelial cells [5, 6].
Survivin is selectively up-regulated in many human tu-
mors, an overexpression of Survivin correlates with poor
outcome, treatment resistance [3] reduced disease free
survival and overall survival of cancer patients [7]. It has
been shown to increase resistance of tumor tissue to
apoptotic stimuli mainly through a Caspase-dependent
mechanism [5]. Small interfering RNA (siRNA) can trig-
ger an RNA interference response in mammalian cells
and induce strong inhibition of specific gene expression
hence they can be used to inhibit cancer-related genes
including Survivin [8].
In-spite of the wide acceptance of TACE a meta-analysis
[9] has demonstrated that 4 of the 6 randomized con-
trolled studies included in the analysis comparing TACE
with untreated controls failed to show any impact of
TACE on patient survival. Keeping into consideration
that there is a great controversy regarding the best
chemotherapeutic agents for TACE [10] the need for
introducing new chemotherapeutic agents targeting
HCC is critical.
Thus, the aim of the current study was to assess the
therapeutic efficacy of the additional transarterial injec-
tion of Survivin siRNA to the regular TACE protocol
compared to the regular TACE protocol in an animal
model of hepatocellular carcinoma, and its effect on
tumor growth, angiogenesis and vascular endothelial
growth factor expression (VEGF) levels.
Methods
Animals and tumor cells
All of the experiments on animals were approved by the
Regional Administrative Authority in Darmstadt, Germany.
Twenty inbred male ACI-rats (Harlan Winkelmann;
Borchen, Germany) weighing 220–240 g were used. The
animals were kept under conventional conditions with a
temperature of 22 ± 2 °C, a relative humidity of 55 ±
10 %, a dark-light rhythm of 12 h, and they were fed
with standard laboratory chow and tap water ad libitum.
The hepatoma cell line used in the current study was
obtained from the German Cancer Research Center
(DKFZ; Heidelberg, Germany). The injected cell line
(Morris hepatoma 3924A) represents a rapidly growing,
poorly differentiated hepatocellular carcinoma.
Chemotherapeutics and agents
For TACE a dose of 0.1 mg Mitomycin (Roche,
Grenzach-Wyhlen, Germany) was dissolved in 0.1 ml
0.9 % NaCl solution 10 min before application. The
embolization was performed using a dose of 0.1 ml lipio-
dol (Guerbet GmbH, Sulzbach, Germany) and 5.0 mg
degradable starch Microspheres (Spherex©, Pharmacia,
Erlangen, Germany).
Survivin siRNA was provided from Ruibo Gentech Co
(Wuhan, PR. China). The target sequence of Survivin
siRNA is as follows: CCGAGAATGAGCCTGATTT. A
dose of 2.5 nmol Survivin siRNA was stable at 2–8 °C
for 10 min before administration.
Anesthesia
A combination of intra-peritoneal injection of Ketamine
Hydrochloride (Ketanest Parke-Davis, Germany;
100 mg/kg), Xylazine Hydrochloride (Rompun, Bayer
Germany; 15 mg/kg) and Atropine Sulfate (Atropin Sul-
fat Braun, Braun, Germany; 0.1 mg/kg) was used for
anesthesia in all Orthotopic, interventional and imaging
procedures.
Tumor implantation (day 0)
The technique for tumor implantation was basically
similar to that described by Yang et al. [11] with minor
modifications [12]. The Morris Hepatoma 3924A tumor
tissue, recovered from the passaged animals 12 days
after subcutaneous implantation (corresponding to 5 ×
106 tumor cells), was cut into small cubes about 2 mm3.
A small sub-capsular incision on the left lateral lobe of
the liver was made in the recipient ACI-rats under
anesthesia. The tumor fragment was gently placed into
created pocket with a small cotton swab on the liver sur-
face and the abdominal wall was then closed.
Interventional therapy (day 13)
For interventional studies a second laparotomy was per-
formed. By using a binocular operative microscope
(M651, Leica; Wetzler, Germany), a PE-10 polyethylene
Micro-catheter (inner diameter 0.28 mm, outer diameter
0.61 mm; Wenzel; Heidelberg, Germany) was retro-
gradely inserted into the Gastro-duodenal artery and
pushed forward to the hepatic artery. Different agents
were then injected into the hepatic artery using the
sandwich technique (subsequent injection of Mitomycin
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+/− Survivin siRNA + Lipiodol + degradable starch Mi-
crospheres) within 20 min. Each group of animals re-
ceived treatment according to the following protocols:
 Group A (TACE+ Survivin siRNA, test group, n = 10):
Mitomycin (0.1 mg) + Lipiodol (0.1 ml) + degradable
starch Microspheres (5.0 mg) + Survivin siRNA
(2.5 nmol)
 Group B (TACE alone, control group, n = 10):
Mitomycin (0.1 mg) + Lipiodol (0.1 ml) + degradable
starch Microspheres (5.0 mg)
MR imaging and analysis (day 12 and 25)
MRI imaging before (on day 12) and after (on day 25)
treatment was performed using a 3.0 Tesla MRI unit
(Magnetom, Siemens; Erlangen, Germany) by using a
wrist coil (Small field of view). T1-weighted (SE: TR/TE,
500/12 ms) and T2-weighted (TSE: TR/TE, 3870/80 ms)
transverse images with a section thickness of 2 mm and
184 × 256 matrix were acquired. There was no gap be-
tween sections and no contrast medium was adminis-
tered. The tumor volume was determined and evaluated
in the T2-weighted image according to the formula [13]:
V = 0.5 × d1 × d22, where d1 is the maximum diameter
of the tumor and d2 is the minimum diameter perpen-
dicular to d1. Image evaluations and size assessments
were performed by a single radiologist with more than
15 years’ experience in abdominal MRI imaging and who
was blinded to the group assignment of the animal in
the study.
Western blot (day 25)
Western blot analysis was carried out to determine the
expression level of the VEGF in the two groups. After
the MRI examination, all the rats were sacrificed using
an over-dose of intravenous Sodium Pentobarbital. To
homogenize the tumors, Precellys Homogenizer IV
(Peqlab Biotechnologie GmbH; Erlangen, Germany) at
4 °C was used in a lysis buffer which is composed of
50 mM HEPES, 200 mM NaCl, 0.2 mM MgSO4,
0.4 mM Phenylmethylsulfonyl fluoride, 2 % Triton- X-
100, 10 μg/mL Leupeptine, 10 μg/mL Aprotinine, 0.02 %
soybean trypsin inhibitor and 0.2 mM Orthovanadate
(Sigma-Aldrich; Taufkirchen, Munich, Germany). The
resulting Cell lysates were centrifuged for 10 min at
12,000 × g at 4 °C. Coomassie Plus protein assay kit
(Pierce; Rockford, IL, USA) was used to measure the
protein concentration in the supernatants. The protein
concentration results were obtained Spectrophotomet-
rically by Tecan Infinite® M 200 microplate reader
(Tecan-Deutschland; Crailsheim, Germany) at 595 nm.
Protein was then denatured in Laemmli sample buffer
(Bio-Rad Laboratories; Munich, Germany) with β mer-
captoethanol (Sigma; Taufkirchen, Germany), boiled for
5 min, and transferred on ice. Sodium Dodecyl Sulfate
Polyacrylamide gel electrophoresis (SDS-PAGE) (50 μg
per lane) was then conducted. The molecular weight
standards used were PeqGold prestained protein
markers IV (Peqlab Biotechnologie GmbH; Erlangen,
Germany). After separation using gel electrophoresis,
protein was blotted onto a Polyvinylidene Difluoride
membrane (Hybond P; GE Healthcare; Munich,
Germany). Blots were then blocked with 10 % low-fat
milk for 1 h at room temperature followed by overnight
incubation at 4 °C with primary antibody from Santa
Cruz Biotechnology (Rabbit polyclonal VEGF 1:200;
Rabbit polyclonal MMP-9 and mouse monoclonal β
Actin, (clone AC-15, 1:1000; Sigma). Blots were then
washed 3 times with Towbin buffer with 0.5 % Tween 20
followed by incubation for 30 min at room temperature
with secondary antibody from Millipore GmbH;
Schwalbach/Ts, Germany (Polyclonal goat Anti-rabbit
IgG, 1:5000; goat Anti-mouse IgG, 1:5000, both HRP
conjugated). All antibodies were diluted in Towbin
Buffer with 0.5 % Tween 20 and 0.5 % bovine serum
albumin. Blots were then washed and incubated withEn-
hanced Chemiluminescence detection kit (GE Healthcare;
Munich, Germany). Signal intensity was finally detected
and captured by Fusion FX-7 (Vilber Lourmat, Marnee la
Vallee, France), documented and analyzed by Bio1D soft-
ware (Vilber Lourmat). β Actin was used as the loading
control.
Immunohistochemical examination (day 26)
The Liver samples were embedded and frozen in a Tissue-
Tek (Sakura, Zoeterwoude, Netherlands) and 5 μM cryo-
sections were prepared. These Sections were fixed in
100 % acetone and equilibrated in PBS followed by over-
night incubation at 4 °C with anti-VEGF rabbit polyclonal
antibody (Santa Cruz Biotechnology Inc., USA) which was
diluted with Dako antibody diluents (DAKO, Hamburg,
Germany). The cryosections were then incubated with
Anti-rabbit Alkaline Phosphatase supervision polymer
system (DCS Innovative Diagnostik-Systeme, Hamburg,
Germany). Staining was visualized using the Neu Fuchsin
substrate Chromogen (DCS Innovative Diagnostik-
Systeme, Hamburg, Germany) and were counterstained
with Hematoxylin and mounted in Kaisers Glycerol Gel-
atin (Merck, Darmstadt, Germany). To evaluate the ex-
pression of VEGF, all slides were examined and scored by
two independent pathologists who were blinded to the
animal data. The percentage staining was scored as
follows: 0 (No staining, 1 (0-5 %), 2 (6-25 %), 3 (26-
50 %), 4 (51-75 %), 5 (76-100 %).
Statistical analysis
The mean tumor growth ratio (V2/V1, V2 tumor vol-
ume after treatment and V1 tumor volume before
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treatment) by MRI and the mean expression ratio
(VEGF/β-actin) level of VEGF by Western blot from
each group were measured and the significance of dif-
ferences between the two groups were analyzed using
the paired-t-test, the statistical software used was
GraphPad Prism (version 3.02, La Jolla, CA, USA).
Immunohistochemical staining of VEGF was evaluated
using descriptive and semi-quantitative methods. The
differences between both groups in the Western-Blot
analysis and Immunohistochemical analysis were
tested for statistical significance using the unpaired-t-
test and the Wilcoxon signed rank test respectively.




Tumor implantation was successful in 100 % of the rats.
Most tumors appeared homogeneous and were hypoin-
tense on T1-weighted images and hyperintense on T2-
weighted images prior to treatment, after treatment the
tumors appeared inhomogenous. After different inter-
ventional treatments, intrahepatic metastases developed
in two of the 10 rats in group B. The means of the vol-
ume ratios (V2/V1) were 1.1313 ± 0.1381 in group A,
and 3.1911 ± 0.1393 in group B. Compared to group B,
group A showed a statistically significant reduction
of the tumor growth within the period of observation
(p < 0.0001) (Fig. 1).
Western blot analysis
VEGF expression level was lower in group A (TACE +
Survivin siRNA) than in group B (TACE alone). There
was a statistically significant difference between group A
and group B regarding the VEGF expression by Western
blot analysis (p < 0.0001) (Fig. 2).
Immunohistochemical assay
The angiogenesis of the tumor was evaluated using the
Anti-VEGF antibodies. VEGF were expressed in all spec-
imens. The Immuno-expression of the protein was con-
firmed by the presence of brown stained cytoplasm in
tumor cells. Higher expression of VEGF in hepatocellu-
lar carcinoma was observed in group B (TACE alone)
with a median histological score of 4.250 compared to
group A (TACE + Survivin siRNA) with a median histo-
logical score of 2.450. The difference between both
groups was statistically significant (p = 0.0020) (Table 1)
(Fig. 3).
Discussion
Since the introduction of TACE as a palliative treatment
in patients with unresectable HCC, it has become one of
the most common forms of interventional therapy [2, 10].
Fig. 1 Transverse unenhanced T2-weighted TSE MR images of solid liver tumor in a group A (TACE+ survivin siRNA) (images a and b) and group
B (control group, TACE alone) (images c and d) in ACI rat. 3870/80 matrix was acquired. a Pretreatment shows a small hyperintense tumor (arrow)
in the left lateral liver lobe (0.55 × 0.54 cm). b Posttreatment demonstrates the same hyperintense tumor lesion (arrow) (0.55 × 0.53 cm) and has
inhomogeneous hypointense area corresponding to intratumoral necrosis. The growth of hepatic tumor is noticeably inhibited after therapy. c
Pretreatment shows a small hyperintense tumor (arrow) in the left lateral liver lobe (0.69 × 0.68 cm). d Posttreatment shows the same (1.14 × 0.98 cm)
tumor (arrow) exhibiting rapid growth compared with its size before therapy. e Mean tumor growth ratio of post-treated (V2) and pre-treated tumor
(V1) by MRI showed significant difference between group A (TACE + survivin siRNA) vs group B (control group, TACE alone)
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TACE reduces the maximum plasma concentration,
lengthens the half-life, and increases the average concen-
tration of chemotherapeutic agents in the tumor [14].
However, post-interventional metastasis and recurrence of
tumors have hindered the curative effect of interventional
therapeutic procedures and the long-term survival rates
[2]. Moreover, a study by Kobayashi et al. [15] showed that
the serum concentration of VEGF was markedly increased
in patients following embolization.
Biologically, Survivin has been shown to inhibit apop-
tosis, enhance proliferation and promote angiogenesis.
High expression levels of Survivin correlate with an
increased rate of tumor recurrence and resistance to
chemotherapy [16]. Several in vitro and in vivo studies
have indicated that Survivin down-regulation is able to
sensitize human tumor cells of different histologic
origins to conventional chemotherapeutic drugs [17].
Another important point to notice is that Survivin plays
an important role in response to Radiotherapy too; a
high level of Survivin has been shown to increase both
the resistance to Radiotherapy and the incidence of local
recurrence in rectal cancer patients [18] and is associ-
ated with worsened survival in patients treated with de-
finitive Radiotherapy for cervical cancer [7, 19].
Similarly, it might be suggested that Survivin expression
might have a similar effect on patient response to Radio-
embolization of hepatic malignancy and that inhibiting
Survivin expression using Survivin siRNA might have a
favorable effect on patient response to Radioemboliza-
tion; similar to what was previously reported by Yang et
al. [20] where the authors reported an enhanced radio-
sensitivity in human hepatoma cells both in vitro and in
vivo in response to Survivin downregulation by Survivin
siRNA. Hence combining Survivin siRNA and Radioem-
bolization might be associated with an improved re-
sponse to Radioembolization, still the medical literature
is lacking such a study.
As Survivin is not a cell surface protein and does not
have an intrinsic enzymatic activity, targeting of Survivin
for therapeutic purposes might be expected to be diffi-
cult. In addition, crystallographic data has revealed few
potential drug able sites on Survivin protein [21]. Be-
cause of the up-regulation of Survivin in malignancy
and its key role in apoptosis, proliferation and angio-
genesis, Survivin is currently attracting considerable
attention as a new target for anti-cancer therapies.
Strategies under investigation to target Survivin in-
clude antisense oligonucleotides, small interfering
RNA (siRNA), ribozymes, immunotherapy and small
molecular weight molecules [22].
Recently, siRNA technology holds a great promise as a
therapeutic intervention for targeted gene silencing in
cancer. RNA interference (RNAi) is a biological mechan-
ism whereby the presence of double-stranded RNA
(dsRNA) interferes with the expression of a particular
gene that shares a homologous sequence with the
dsRNA. Recent studies have provided insights into the
molecular mechanisms of RNAi, in which dsRNA in-
duces the silencing of homologous mRNA. In the cyto-
plasm of mammalian cells, an enzyme known as Dicer
initiates RNA silencing by the breakdown of long dsRNA
to generate siRNA of about 21–23 nucleotides in length.
The resulting siRNAs are incorporated into an RNA-
induced silencing complex (RISC) and unwound into a
single-stranded RNA (ssRNA), which is followed by the
degradation of ssRNA [23]. siRNA is 10–100-fold more
Fig. 2 Inhibitory effects of survivin siRNA on the expression of VEGF
by Western blot analysis. a VEGF bands in group A (TACE + survivin
siRNA) was suppressed compared to TACE alone (control). Depicted
are representative bands from 10 independent experiments (N = 10)
(b) Shows the semi quantification of proteins bands, expressed as
ratio of VEGF / β-actin. Group A (TACE + survivin siRNA) was down
regulated compared to Group B (TACE alone) (N = 10)
Table 1 Immunuhistochemical expression of VEGF in
hepatocellular carcinoma







VEGF 2.450 4.250 0.0020
Scoring: 0 (No staining), 1 (0-5%), 2 (6-25%), 3 (26-50%), 4 (51-75%),
5 (76-100%).
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potent for gene silencing, making it attractive tool for
silencing of target genes in cancer [24]. An Adenovirus-
mediated siRNA expression vector was reported to de-
crease Survivin expression of the established HCC
tumor in nude mice. In vitro study showed that stable
Survivin-knockdown inhibited cancer cell proliferation,
enhanced apoptotic susceptibility, arrested cell cycle in
the G1 phase and resulted in an apparent mitotic catas-
trophe. An additional in vivo study showed that intra-
tumoral injection of Adenovirus-delivered Survivin
siRNA suppressed tumor growth by spontaneous apop-
tosis of cancer cells and significantly prolonged animal
survival [25]. However, in vivo systemic delivery of
siRNA-based therapeutics to tumor tissues/cells remains
a challenge. The major limitations against the use of
siRNA as a therapeutic tool are its degradation by serum
nucleases, poor cellular uptake, nonspecific immune
stimulation and rapid renal clearance following systemic
administration [24, 26].
The current study was designed to reduce tumor
progression by using a combination of transarterial
administration of Survivin siRNA and TACE using the
sandwich technique in an animal model of HCC. We did
not include intravenous delivery approach because the
transarterial route was much more efficient in the treat-
ment of HCC. In the current study however we did not
evaluate the expression of Survivin directly in the Hepa-
toma 3924a in addition we did not assess the degree of
suppression of Survivin expression in response to treat-
ment for several reasons. First the expression of Survivin
has been reported to occur in several HCC cell lines and
in human HCC tissue [27], it has been reported to be
highly expressed in the vast majority of human cancers
including HCC [28]. Second we relied on the radiologic
oncologic assessment of the therapeutic effect of Survi-
vin siRNA rather than on its direct assessment. A direct
assessment of the suppression of Survivin was rather
outside the scope of the current study. Finally Survivin
expression has been shown to significantly correlate with
VEGF expression in HCC [29], hence we relied on this
correlation to indirectly assess Survivin suppression
(through VEGF assessment). Still we regard this as one
Fig. 3 The immunohistochemical staining of VEGF in hepatocellular carcinoma. a VEGF staining in hepatocellular carcinoma in the group A
(TACE + survivin siRNA) (×100). b Significantly higher VEGF staining in hepatocellular carcinoma was observed in group B (control group,
TACE alone) than group A (×100). c Median histological score of VEGF (N = 10)
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of the limitations of the study and recommend the sub-
ject for further evaluation in future studies assessing not
only the response based on radiologic evidence but
based on direct assessment of Survivin. Another limita-
tion of the current study is the lack of a negative control
group (receiving si-control RNA).
Survivin has been shown to play an important role in
the regulation of expression of VEGF in breast cancer
lymphatic metastases [30]. In addition it has been shown
to significantly correlate with the expression with VEGF
in hepatocellular carcinoma and promote the expression
of VEGF [28, 29]. Our experimental results demon-
strated that groups A (TACE + Survivin siRNA)
showed a significant reduction of tumor growth in
the period of observation compared to the control
group (TACE alone). Higher Immunohistochemical ex-
pression of VEGF in hepatocellular carcinoma was ob-
served in group B (TACE alone) than that of group A
(TACE + Survivin siRNA) (P < 0.01). The invasive progres-
sion of tumor cells in group A was noticeably inhibited
compared with group B. This complex targeting treatment
method seemed to overcome the insufficiency of TACE
and improve the overall therapeutic effects.
Conclusion
In conclusion, the additional injection of Survivin siRNA
to the routine protocol of TACE has shown to be safe
and effective in an animal model of HCC in rats. This
combined therapeutic therapy noticeably inhibited the
growth of the hepatic carcinoma in rats compared with
TACE alone. Further experimental studies will be re-
quired to fully understand the benefits and risks of this
strategy for treating HCC before transferring it to hu-
man studies.
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